BACE Inhibitors Fail Safety Controls for Alzheimer’s Drugs

Clinical trials for BACE inhibitors, thought to be a possibility for Alzheimer’s treatment, were stopped last week because of potential toxicity problems. BACE inhibitors are a drug class known as beta secretase. This particular study was being conducted by Eli Lilly, though other companies have been testing similar drugs.   The need to stop the BACE study represents another significant blow to drug companies in their race to...
Source: Carol Bradley Bursack's SharePosts - Category: Dementia Authors: Source Type: blogs